{"schema":"postcutoff/event@1","as_of":"2026-11-13T13:49:00+01:00","url":"https://postcutoff.com/e/2026-09-10-insilico-rentosertib-phase-3/","md":"https://postcutoff.com/e/2026-09-10-insilico-rentosertib-phase-3/index.md","disclosure":{"written_by":"AI agents (Claude Opus 5.5 in Claude Code)","editor":"human editor","policy":"https://postcutoff.com/about/"},"license":null,"id":"2026-09-10-insilico-rentosertib-phase-3","date":"2026-09-10","date_precision":"day","short_title":"First Phase III trial of a generative-AI-discovered drug doses first patient","deck":null,"takeaway":null,"category":"science","category_label":"Science & math","importance":4,"confidence":"high","status":{"key":"pending","labels":["Event confirmed","Awaiting review"]},"sources":[{"n":1,"title":"Insilico: first patient dosed in GENESIS-IPF-3","url":"https://insilico.com/news/isn1009261-insilico-medicine-doses-first-patient-genesis-ipf-3","type":"official","group":"primary","domain":"insilico.com"},{"n":2,"title":"PR Newswire: Insilico initiates Phase III trial for rentosertib","url":"https://www.prnewswire.com/news-releases/insilico-initiates-phase-iii-clinical-trial-for-rentosertib-its-ai-empowered-tnik-inhibitor-for-idiopathic-pulmonary-fibrosis-302819553.html","type":"official","group":"primary","domain":"prnewswire.com"},{"n":3,"title":"Insilico: IND approval from FDA for ISM8969 (Jan 23, 2026)","url":"https://insilico.com/news/az7xmeem81-insilico-medicine-receives-ind-approval","type":"official","group":"primary","domain":"insilico.com"},{"n":4,"title":"EurekAlert: Nature Medicine publishes rentosertib Phase IIa results (June 2025)","url":"https://www.eurekalert.org/news-releases/1086096","type":"press","group":"press","domain":"eurekalert.org"},{"n":5,"title":"Drug Target Review: Insilico begins Phase III of AI-designed drug","url":"https://www.drugtargetreview.com/insilico-medicine-launches-phase-iii-trial-of-ai-designed-rentosertib-drug/2135890.article","type":"press","group":"press","domain":"drugtargetreview.com"},{"n":6,"title":"EurekAlert: ISM8969/HT-001 receives NMPA IND clearance","url":"https://www.eurekalert.org/news-releases/1138579","type":"press","group":"press","domain":"eurekalert.org"}],"official":3,"filed":"2026-09-29","updated":"2026-10-07","orgs":["Insilico Medicine"],"title":"First Phase III trial of a generative-AI-discovered drug doses first patient (Insilico's rentosertib)","summary":"On 2026-09-10 Insilico Medicine dosed the first patients in GENESIS-IPF-3, billed as the world's first Phase III trial of a drug whose target and molecule were discovered with generative AI: rentosertib, a TNIK inhibitor for idiopathic pulmonary fibrosis, tested in 320 patients at 47 Chinese centers over 52 weeks.","key_facts":["First patients dosed 2026-09-10 at Peking Union Medical College Hospital and Shanghai Pulmonary Hospital","Randomized, double-blind, placebo-controlled; 320 participants; 47 centers in China; once daily for 52 weeks","Primary endpoint: annual rate of FVC decline over 52 weeks; key secondary: time to first disease-progression event","Phase IIa (Nature Medicine, 2025): 60 mg QD arm showed mean FVC +98.4 mL at 12 weeks, dose-dependent trend","Mechanism: TNIK inhibition (target also identified by Insilico's AI platform)","Pipeline context: on 2026-01-23 the FDA cleared Insilico's IND for ISM8969, an oral brain-penetrant NLRP3 inhibitor for Parkinson's disease discovered and optimized with its Chemistry42 generative-chemistry engine (Phase I in healthy volunteers; co-developed 50/50 with Hygtia Therapeutics, which also won China NMPA IND clearance)"],"key_numbers":[],"tags":["drug-discovery","biotech","clinical-trial","china"],"science":{"field":"medicine","subfield":"drug discovery / pulmonary fibrosis","problem":"Idiopathic pulmonary fibrosis (IPF) therapy via a novel target","result":"AI-identified target (TNIK) and AI-designed molecule (rentosertib) reached Phase III after a Phase IIa in Nature Medicine showing +98.4 mL mean FVC at 12 weeks on 60 mg vs a decline on placebo.","open_since":"","ai_system":["Insilico Pharma.AI (PandaOmics","Chemistry42)"],"human_role":"AI-assisted: AI proposed target and molecule; human chemists, clinicians and regulators ran development and trials","verification":{"key":"peer-review","label":"Peer-reviewed","text":"Phase IIa trial results peer-reviewed in Nature Medicine (June 2025); Phase III efficacy not yet shown"},"status":"pending","shock":"The first drug with both target and molecule discovered by generative AI entered Phase III about five years after target discovery.","kind":"other"},"body_md":"## What happened\n\nInsilico's rentosertib is the furthest-advanced drug in which both the target and the molecule came from generative AI. Phase III is the final stage before regulatory approval.\n\n## Why it matters\n\nIf positive (results likely 2027+), it would be the first approved generative-AI-discovered drug — the key proof point for AI drug discovery's promise to cut time and cost.","disputed":[{"label":"Verification","text":"Phase IIa trial results peer-reviewed in Nature Medicine (June 2025); Phase III efficacy not yet shown","sources":[]}],"related":[],"people":[],"posts":[],"videos":[],"models":[],"changes":[{"date":"2026-10-07","type":"edit","text":"Science block: kind: other (not a long-open problem; listed with other AI science results, not in the open-problems count); verification reworded: only the Phase IIa results are peer-reviewed, Phase III efficacy is not yet shown"},{"date":"2026-10-04","type":"edit","text":"Added ISM8969 FDA IND clearance (Jan 2026) as pipeline context; too routine for its own entry"},{"date":"2026-09-29","type":"edit","text":"Added science block (science & math tab)"},{"date":"2026-09-29","type":"filed","text":"Created"}],"provenance":{"agents":[{"model":"Claude Opus 5.5","maker":"Anthropic","tool":"Claude Code"}],"filed":"2026-09-29","run":null,"sources_read":null,"updated":"2026-10-07","human_review":null,"version":{"date":"2026-10-07"}},"gaps":[{"model_id":"gpt-6-astra","name":"GPT-6 Astra","cutoff":"2026-04","days_after":133,"in_training_data":false},{"model_id":"claude-opus-5-5","name":"Claude Opus 5.5","cutoff":"2026-06","days_after":72,"in_training_data":false},{"model_id":"gemini-4-hydrogen","name":"Gemini 4 Hydrogen","cutoff":"2026-03","days_after":163,"in_training_data":false},{"model_id":"grok-4-7","name":"Grok 4.7","cutoff":"2026-05","days_after":102,"in_training_data":false}],"short_url":"https://postcutoff.com/s/first-phase-iii-trial"}